About Trinomab 

Zhuhai Trinomab Biopharmaceutical Co., Ltd. (hereafter referred to as "Trinomab"), is a biopharmaceutical company dedicated to developing and commercializing the innovative therapeutics on a global scale. Founded in 2015 and guided by the philosophy "Creating Clinical Value for Patients", the company is committed to advancing its proprietary HitmAb® technological platform. This platform facilitates the discovery and manufacturing of fully human monoclonal antibodies (mAbs), which serve as alternatives to blood-derived immunoglobulin products. 

Trinomab current pipeline includes multiple promising antibody drug candidates that are targeting the therapeutic areas such as certain infectious diseases and pain-related or autoimmune disordes, where the effective treatment are still under development. For example,Trinomab first commercial product, Siltartoxatug Injection，is the first-in-class and has been approved for the market launch in China. Siltartoxatug Injection is the first domestically developed anti-infective biologic drug designated as a breakthrough therapy by the CDE in China. The results of its Phase III clinical trial were highlighted by the oral presentations at both the 2024 American College of Emergency Physicians (ACEP) Annual Meeting and the 18th European Emergency Medicine Congress (EUSEM) in 2024. The clinical data had demonstrated the unparalleled effectiveness of tetanus prophylaxis. Another example, TNM001, as one of key products under development, is a monoclonal antibody targeting respiratory syncytial virus (RSV), is currently at Phase III clinical trials. With well demonstrated efficacy of TNM001 against RSV infection in children, it would be expected to become the world's third (yet first in China) long-acting monoclonal antibody for RSV prevention, especially for the treatment of children and infants.

Driven by the philosophy "Creating Clinical Value For Patients," and armed with the innovative HitmAb® technologies, the company is pursuing its commitment to the development, manufacturing, and commercialization of fully human monoclonal antibody drugs with the highest efficacy and safety for the patients globally.